Three scientists were awarded this year’s Tang Prize in Biopharmaceutical Science for discovering the Glucagon-like peptide-1 (7-37) (GLP-1 (7-37)) which stimulates insulin secretion and can be used in medication combating diabetes and obesity, the Tang Prize Selection Committee announced in Taipei yesterday.
The three laureates — Joel Habener, Svetlana Mojsov and Jens Juul Holst — were presented the award for “the discovery of GLP-1 (7-37) as having an insulinotropic factor and the development of GLP-1 (7-37)-based anti-diabetic and anti-obesity drugs,” said Chang Wen-chang (張文昌), chair of the Tang Prize Selection Committee for Biopharmaceutical Science and an academic at Academia Sinica.
The laureates’ discoveries laid the foundation for the further development of GLP-1 (7-37), a 31-amino acid peptide, by other scientists. The result has been the development of blockbuster drugs that have benefited hundreds of millions of users and have great prospects, said Academia Sinica’s Kung Hsing-jien (龔行健), who introduced the laureates’ major contributions.
Photo: CNA
Their work surrounding GLP-1 (7-37) is also “an exemplary story of translating basic research into pharmaceutical success with major impacts on human health,” Kung said, adding that there are more than 500 million people with diabetes and about 1 billion obese individuals in the world.
Type 2 diabetes, which makes up about 90 percent of the world’s cases, occurs because pancreas beta cells do not secrete enough insulin, a peptide hormone that lowers blood glucose levels. The body also cannot respond to insulin properly, which causes high blood sugar and leads to severe complications.
On the other hand, obesity raises the risk of various diseases and is regarded as one of the most important global public health issues.
The work toward discovering that GLP-1 (7-37) has an insulinotropic factor — meaning it stimulates insulin secretion — dates back to the early 1980s. Habener, a physician at the Massachusetts General Hospital (MGH) and an emeritus professor of medicine at Harvard Medical School, then published the results of cloning the preproglucagon gene from anglerfish.
Specializing in endocrinology and metabolism, Habener found that preproglucagon, a precursor protein, contains glucagon — a peptide hormone that raises blood glucose levels — along with another glucagon-related peptide (GRP).
Subsequent cloning of the preproglucagon gene from rats showed that it contained glucagon and two additional peptides designated GLP-1 and GLP-2, and that the GRP from anglerfish is a form of GLP-1.
Habener then collaborated with Mojsov, the head of a peptide synthesis facility at MGH who identified GLP-1 (7-37) as the active form of intestinal GLP-1. Together they showed that GLP-1 (7-37) induces insulin release from the pancreas, as opposed to the entire GLP-1 (1-37) — the whole peptide.
The discovery was critical in identifying the long-sought-after incretin — a type of hormone released from the gut after eating, which stimulates insulin secretion from the pancreas in response to food intake — and led to GLP-1 (7-37) being used in diabetes medication, an award citation released by the Tang Prize Foundation said.
Mojsov made significant contributions to GLP-1 (7-37), through synthesizing — chemically creating — the peptide in the mid-80s, it said, adding that she also developed several important experimental approaches to detect the GLPs in the intestine.
She later collaborated again with Haberner and further demonstrated through human subject research that GLP-1 (7-37) stimulates insulin production, paving the way for its use in clinical settings.
Independently, Holst at the University of Copenhagen also isolated and identified GLP-1 (1-37), and subsequently the GLP-1 (7-36) amide — another truncated form of GLP-1 that is equally potent as GLP-1 (7-37) — as an active incretin in the mid-to-late 1980s.
He was also lauded by the foundation for characterizing the biology and physiology of GLP-1 (7-37), demonstrating its therapeutic potential and contributing to the development of anti-diabetic drugs.
The findings of Habener, Mojsov and Holst collectively led to an era of GLP-based drugs being used to treat diabetes from 2005 and obesity from 2014. More people have started using these medications over the past few years.
During clinical trials, it was observed that patients receiving GLP-based drugs experienced weight loss. Further studies revealed that GLP-1 receptors in the human brain could suppress appetite and treat obesity.
Holst also reported that GLP-1 (7-37) reduces stomach acid and slows gastric emptying, the foundation said.
After years of pharmaceutical development, there are at least 13 GLP-1 receptor agonist drugs — medications that mimic the actions of incretin and activate the GLP-1 receptor — approved by the US Food and Drug Administration for treating diabetes, obesity or both, the foundation added.
Taipei and New Taipei City government officials are aiming to have the first phase of the Wanhua-Jungho-Shulin Mass Rapid Transit (MRT) line completed and opened by 2027, following the arrival of the first train set yesterday. The 22km-long Light Green Line would connect four densely populated districts in Taipei and New Taipei City: Wanhua (萬華), Jhonghe (中和), Tucheng (土城) and Shulin (樹林). The first phase of the project would connect Wanhua and Jhonghe districts, with Chiang Kai-shek Memorial Hall and Chukuang (莒光) being the terminal stations. The two municipalities jointly hosted a ceremony for the first train to be used
The Mainland Affairs Council (MAC) yesterday said it is fully aware of the situation following reports that the son of ousted Chinese politician Bo Xilai (薄熙來) has arrived in Taiwan and is to marry a Taiwanese. Local media reported that Bo Guagua (薄瓜瓜), son of the former member of the Political Bureau of the Central Committee of the Communist Party of China, is to marry the granddaughter of Luodong Poh-Ai Hospital founder Hsu Wen-cheng (許文政). The pair met when studying abroad and arranged to get married this year, with the wedding breakfast to be held at The One holiday resort in Hsinchu
Tropical Storm Usagi strengthened to a typhoon this morning and remains on track to brush past southeastern Taiwan between Friday and Sunday, the Central Weather Administration (CWA) said. The storm, which as of 8am was still 1,100km southeast of southern Taiwan, is currently expected to enter the Bashi Channel and then turn north, moving into waters southeast of Taiwan, the CWA said. Because of its rapid speed — 28kph as of 8am — a sea warning for the storm could be issued tonight, rather than tomorrow, as previously forecast, the CWA said. In terms of its impact, Usagi is to bring scattered or
An orange gas cloud that leaked from a waste management plant yesterday morning in Taoyuan’s Guanyin District (觀音) was likely caused by acidic waste, authorities said, adding that it posed no immediate harm. The leak occurred at a plant in the district’s Environmental Science and Technology Park at about 7am, the Taoyuan Fire Department said. Firefighters discovered a cloud of unidentified orange gas leaking from a waste tank when they arrived on the site, it said, adding that they put on Level A chemical protection before entering the building. After finding there was no continuous leak, the department worked with the city’s Department
RSS